Cipla Shares in Focus as USFDA Classifies Inspection as VAI
Cipla shares are expected to remain in focus after the United States Food and Drug Administration (USFDA) classified the inspection of its Virgonagar, Bengaluru facility as Voluntary Action Indicated (VAI). The routine current Good Manufacturing Practices (cGMP) inspection was conducted between November 7-13, 2024. Earlier this month, Cipla announced an investment of ZAR 900 million […]
Cipla Shares in Focus as USFDA Classifies Inspection as VAI Read More »